Sort
15,273 grants matching “antimicrobial resistance”
Post-PCV pneumococcal population genetics and resistance
$647,359Jonathan A Finkelstein · Harvard Pilgrim Health Care, Inc. · R01 · FY2008 · AI
WHO-recommended Periodic Presumptive Treatment versus Doxycycline Post-Exposure Prophylaxis for STI Control among Cisgender Men Who Have Sex with Men in Kenya
$646,815Susan Marie Graham · University Of Washington · R01 · FY2025 · AI
Regulation of Pseudomonas syringae Virulence by Plant-Derived Chemical Signals
$646,724Jeffrey C Anderson · Oregon State University · · FY2016 · BIO
Risk factors for drug resistant pneumococcal bacteremia
$646,687Joshua P Metlay · University Of Pennsylvania · R01 · FY2009 · AI
Improving Quality of Care for the Treatment of Childhood Pneumonia
$646,324Patricia L Hibberd · Tufts University Boston · U01 · FY2009 · HD
Plasma-based therapies for bone infection: A tripartite USA/Northern Ireland/Republic of Ireland consortium
$646,298Theresa A Freeman · Thomas Jefferson University · R01 · FY2024 · AR
Antimicrobial Peptide Treatment to Combat Wound Biofilm
$646,195Jennifer Ann Neff · Allvivo Vascular, Inc. · R44 · FY2021 · AI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
$646,188Qi Zhou · Purdue University · R01 · FY2023 · AI
Advancing innovative therapies against pandrug-resistant Gram-negative superbugs
$646,174Qi Zhou · Purdue University · R01 · FY2021 · AI
Role of Molecular Chaperones in Stress Response and Disease
$646,156Ursula H Jakob · University Of Michigan At Ann Arbor · R35 · FY2020 · GM
Role of Molecular Chaperones in Stress Response and Disease
$646,156Ursula H Jakob · University Of Michigan At Ann Arbor · R35 · FY2021 · GM
Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus disease
$646,138M. Javad Aman · Abvacc, Inc. · R01 · FY2025 · AI
DEVELOPMENT OF BROAD SPECTRUM ANTIVIRALS
$646,100Urban Ramstedt · Unither Virology, Llc · N01 · FY2013 · AI
Innate Immune Control of TB and HIV
$646,050Anne Goldfeld · Boston Children'S Hospital · R56 · FY2021 · AI
Repurposing novel selective drugs for treatment and decolonization of vancomycin resistant enterococci
$645,971Mohamed Seleem · Virginia Polytechnic Inst And St Univ · R01 · FY2021 · AI
Rapid fungal identification and antifungal susceptibility testing through quantitative, multiplexed RNA detection
$645,818Roby Paul Bhattacharyya · Broad Institute, Inc. · R01 · FY2020 · AI
Anti-viral Mechanisms of Defensins
$645,771Jason G Smith · University Of Washington · R01 · FY2023 · AI
Transferrin Combination Therapy to Address Antimicrobial Resistance
$645,650Brad J Spellberg · University Of Southern California · R01 · FY2019 · AI
Genetic Analysis of Toxinogenesis in Vibrio Cholerae
$645,629John J Mekalanos · Harvard Medical School · R01 · FY2010 · AI
Innate, Transcriptomic, and Microbiomic correlates of TB infection
$645,460Michael Haggai Glickman · Weill Medical Coll Of Cornell Univ · U19 · FY2015 · AI
Role of epithelial ROS signaling in mediating psychological stress-induced mucosal dysfunction and colitis predisposition
$644,907Jacob Matthew Allen · University Of Illinois At Urbana-Champaign · R01 · FY2025 · DK
Salivary peptide/protein-based multilayer denture coatings for controlling Candida biofilm formation and denture stomatitis
$644,760Yuyu Sun · University Of Massachusetts Lowell · R01 · FY2024 · DE
Sensor Technology for Rapid Microbial Identification and Susceptibility Testing
$644,605David A Haake · Brentwood Biomedical Research Institute · U01 · FY2008 · AI
Development of human adaptive immunity to Staphylococcus aureus
$644,454Juliane Bubeck Wardenburg · Washington University · R01 · FY2021 · AI
DNA gyrase and quinolone resistance in tuberculosis
$644,419Karl A Drlica · Public Health Research Institute · R01 · FY2006 · AI